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OBJECTIVES We sought to evaluate the changing outcomes of percutaneous coronary interventions (PCIs)
in recent years.
BACKGROUND The field of interventional cardiology has seen considerable growth in recent years, both in the
number of patients undergoing procedures and in the development of new technology. In
view of recent changes, we evaluated the experience of a large, regional registry of PCIs and
outcomes over time.
METHODS Data were collected from 1990 to 1997 on 34,752 consecutive PCIs performed at all hospitals
in Maine (two), New Hampshire (two) and Vermont (one) supporting these procedures, and
one hospital in Massachusetts. Univariate and multivariate regression analyses were used to
control for case mix. Clinical success was defined as at least one lesion dilated to ,50%
residual stenosis and no adverse outcomes. In-hospital adverse outcomes included coronary
artery bypass graft surgery (CABG), myocardial infarction and mortality.
RESULTS Over time, the population undergoing PCIs tended to be older with increasing comorbidity.
After adjustment for case mix, clinical success continued to improve from a low of 88.2% in
earlier years to a peak of 91.9% in recent years (p trend ,0.001). The rate of emergency
CABG after PCI fell in recent years from a peak of 2.3% to 1.3% (p trend ,0.001). Mortality
rates decreased slightly from 1.2% to 1.1% (p trend 0.007).
CONCLUSIONS There has been a significant improvement in clinical outcomes for patients undergoing PCIs
in northern New England, including a significant decline in the need for emergency CABG.
(J Am Coll Cardiol 1999;34:674–80) © 1999 by the American College of Cardiology
The practice of percutaneous coronary interventions (PCIs)
continues to evolve. Since Andreas Gruentzig performed
the first human coronary angioplasty in September 1977 (1),
the field has rapidly expanded to an estimated 1 million
PCIs performed worldwide each year (2). Over the past
20 years, the increasing experience of operators (3,4)
coupled with the advent of newer technologies, including
coronary stents (5) and a variety of adjuvant drug thera-
pies (6 – 8), have permitted more successful procedures
and decreased the morbidity associated with PCIs (9). In
May of 1994, the Palmaz-Schatz stent was recommended
for approval by the Food and Drug Administration
advisory panel for elective use in selected patients to
prevent restenosis after angioplasty (10). Later that year,
results from the Benestent Study Group (11) and the
Stent Restenosis Study (12) were published. The use of
coronary stents in PCIs subsequently increased dramati-
cally, and it is estimated that nearly 50% of all PCIs now
involve stents (2).
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Although many randomized trials have described improv-
ing outcomes for PCIs, there are few large observational
trials examining the generalizability of these results (13,14).
Several randomized studies have documented improvement
with respect to abrupt closure and restenosis (11,12). A
recent study comparing the National Heart, Lung, and
Blood Institute (NHLBI) Registry (1985 to 1986) with the
New Approaches to Coronary Intervention (NACI) Regis-
try (1990 to 1994) suggests progress remains to be seen with
respect to long-term survival after PCIs (15).
The Northern New England Cardiovascular Disease
Study Group (NNECVDSG) is a voluntary research con-
sortium composed of clinicians, research scientists and
hospital administrators. The focus of the group is to foster
continuous improvement in the quality of care of patients
with cardiovascular disease in northern New England
through the analysis of process and outcome data combined
with the timely feedback of data to clinicians (16,17). We
used our prospective, multicenter, clinical database to eval-
uate the overall improvement in outcomes for patients after
PCIs in our region from 1990 to 1997.
METHODS
Patient population. Data were prospectively collected on
34,752 consecutive PCIs performed from January 1990
through December 1997 at all hospitals in Maine (2), New
Hampshire (2) and Vermont (1) supporting these proce-
dures, and one hospital in Massachusetts. Not all cardiolo-
gists contributed from the beginning of data collection, and
some left the practice of invasive cardiology or the region
before the end of the study. However, cardiologists were
required to report on all cases performed at these institu-
tions while participating in the study. Given the advent of
stent technology during the study period, data were divided
into early (1990 to 1993; 0% of cases involving stents),
transitional (1994 to 1995; 3.9% of cases involving stents)
and current years (1996 to 1997; 48.5% of cases involving
stents). The transitional period is intended to mark the
widespread introduction of stent technology to the field of
PCIs.
Data collection. Data for each PCI were recorded on
separate forms at the time of the procedure. Demographic
and comorbidity data included age, gender, previous PCIs,
previous coronary artery bypass graft surgery (CABG),
previous myocardial infarction (MI), presence of diabetes,
history of peripheral vascular disease and history of chronic
obstructive pulmonary disease. Previous MI was defined as
a MI occurring at least three weeks before the intervention.
Clinical data included the indication for the procedure,
the priority of the procedure (emergency, urgent and non-
urgent), whether the patient was on intravenous (IV)
nitroglycerin or IV heparin, whether the patient had an
intraaortic balloon pump (IABP) in place before the inter-
vention and ejection fraction (EF). Angiographic data
included the presence of a .50% left main stenosis, whether
the patient had .70% stenoses in the left anterior descend-
ing (LAD), circumflex, right coronary artery or in a bypass
graft, dominance, the number of lesions attempted, inter-
ventional devices used and the location and complexity of
the treated lesion(s). Lesion complexity was defined using
the American College of Cardiology definitions for type A,
B and C lesions (18), with B lesions broken down to B1 and
B2 lesions starting in 1994 (19). Percent stenoses before and
after inflations were recorded by the primary operator using
visual estimates or calipers depending on the local standard.
Successful and adverse outcomes occurring during the
PCI hospitalization were assessed. Clinical success was
defined as at least one lesion dilated with ,50% residual
stenosis and no adverse outcomes (20,21). Adverse out-
comes assessed during the hospitalization included any
CABG (emergency or nonemergency CABG), new MI or
death. Emergency CABG was defined as surgery performed
to treat acute closure, unstable angina or congestive heart
failure (CHF) requiring IV nitroglycerin or IABP or tam-
ponade resulting from the intervention. Nonemergency
CABG was defined as surgery performed after an unsuc-
cessful PCI in a stable patient during the same hospitaliza-
tion. A new MI was defined as a clinical event, electrocar-
diogram (ECG) changes and a creatine phosphokinase
(CPK) rise to greater than or equal to twice normal levels
with positive isoenzymes.
To ensure that data were collected for all eligible patients
and that the outcomes of CABG and death were correctly
assessed, the data collection was validated. Hospitals pro-
vided lists of discharge abstracts for patients and catheter-
ization laboratory logs for comparison with the registry to
identify patients for whom forms were missing. Any missing
information was then obtained. Hospital discharge abstracts
served as the “gold” standard for validating the outcomes of
CABG and death. Myocardial infarctions were not sepa-
rately validated.
Statistical analysis. All analyses were carried out using
Statistical Analysis Software version 6.11 (Cary, North
Carolina) or STATA Statistical Software, Release 5.0
(College Station, Texas). Treatment variables including
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CPK 5 creatine phosphokinase
DCA 5 directional coronary atherectomy
EF 5 ejection fraction
IABP 5 intraaortic balloon pump
LAD 5 left anterior descending coronary artery
MI 5 myocardial infarction
NNECVDSG 5 Northern New England
Cardiovascular Disease Study Group
PCI 5 percutaneous coronary intervention
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preprocedure IV heparin, IV nitroglycerin, thrombolytics
and IABP were coded as “not present” if the value was
missing under the assumption that a recording would have
been made had the therapy been present. Procedures with
missing values for gender were excluded from the multivar-
iate analysis. Ejection fraction was not reported in 41% of
cases. For these patients, values for EF were imputed based
on a prediction model generated from the remaining data
set (Appendix A). Pearson chi-square tests were used to
assess the univariate association between potential predictors
and the outcome variables of clinical success, new MI, CABG
and death (22). All variables demonstrating a univariate asso-
ciation with the event of interest at a p value , 0.10 (without
adjustment for multiple comparisons) were considered poten-
tial independent variables for inclusion in the multivariate
analyses. Multivariate analyses were conducted using logistic
regression models (23). Age and gender were included in all
models. Adjusted rates for successful and adverse outcomes
were calculated using the beta estimates from the logistic
regression model and direct standardization (24).
RESULTS
Three periods of time corresponding to the increased use of
coronary stents were utilized to describe our patient popu-
lation (early: January 1990 to December 1993; transitional:
January 1994 to June 1995; current: July 1995 to December
1997). Table 1 describes the clinical characteristics of the
Northern New England patient population over the entire
study period. More recent years have seen PCIs involving an
older patient population overall. In addition to more pa-
tients with renal failure undergoing PCIs, similar propor-
tions of patients suffered from concomitant diabetes melli-
tus, peripheral vascular disease and chronic obstructive
pulmonary disease. A smaller proportion of patients in
recent years had a history of previous MI or PCI, and a
larger proportion had undergone a previous CABG or had
a history of congestive heart failure.
The procedural characteristics and indications changed
over time (Table 2). A larger proportion of cases were
performed in an emergency setting, partially accounted for
by the increased use of PCI as the primary therapy for MI.
Cases tended to involve more complex lesions over time; there
were more type B2 and type C lesions and more lesions in
bypass grafts. An impressive change in the use of new devices
was seen with no stents used in the early 1990s to nearly 50%
of cases involving stents at the end of the study period.
Data regarding outcomes after PCIs are presented in
Table 3. With respect to unadjusted rates, clinical success
Table 1. Clinical Characteristics of Patients Undergoing PCIs by Year of Procedure
Characteristic
Year
p
Trend*
1990–1993
(n 5 13,014)
1994–6/95
(n 5 7,248)
7/95–1997
(n 5 14,490)
Age (mean) 60.9 61.3 61.9 , 0.001
Age $80% 4.0 5.6 6.3 , 0.001
Female (%) 31.4 32.3 32.4 0.631
Body surface area (m2) — 1.96 1.97 , 0.001
Creatinine (mg/dl) — 1.1 1.1 0.435
Comorbidities (%)
Diabetes mellitus 21.2 21.4 22.3 0.021
Vascular disease — 9.8 10.4 0.144
COPD — 8.9 9.2 0.413
Renal failure — 1.4 2.6 , 0.001
Prior cardiac history (%)
Previous MI 29.8 26.5 23.5 , 0.001
Previous PCI 26.7 30.5 25.7 , 0.001
Previous CABG 10.5 13.3 15.4 , 0.001
Congestive heart failure — 4.5 7.2 , 0.001
Cardiac anatomy and function (%)
Three-vessel disease 11.1 11.4 11.5 0.326
$50% Left main disease 1.8 2.2 3.7 , 0.001
EF ,40% 5.2 3.9 5.5 0.212
Preprocedure treatment (%)
Heparin 50.3 56.3 50.4 0.769
Intravenous nitroglycerin 21.3 27.3 21.2 0.666
Thrombolytic 7.9 8.6 6.4 , 0.001
IABP 0.4 0.3 0.4 0.584
*Analysis of variance for continuous variables.
CABG 5 coronary artery bypass grafting surgery; COPD 5 chronic obstructive pulmonary disease; EF 5 ejection fraction;
IABP 5 intraaortic balloon pump; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
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increased over the study period to 91.5% in recent years.
Rates of MI and both emergency and nonemergency
CABG declined over time. A slight increase in the rate of
in-hospital mortality was seen over time.
Adjusted rates for these same in-hospital outcomes are
also presented in Table 3. After adjusting for case mix,
clinical success and rates of adverse outcomes continued to
improve over the study period. In particular, rates of CABG
Table 2. Indication, Priority, and Procedural Characteristics of Patients Undergoing PCIs by
Year of Procedure
Characteristic
Year
p Trend*1990–1993 1994–6/95 7/95–1997
Priority for first procedure (%)
Emergency 6.4 8.9 8.8 , 0.001
Urgent 58.3 55.6 56.5 0.003
Nonurgent 35.3 35.5 34.7 0.334
Indication for first procedure (%)
Stable angina 24.4 22.4 22.5 , 0.001
Unstable angina 71.4 70.4 70.7 0.245
Primary therapy for MI 2.5 4.1 5.2 , 0.001
Cardiogenic shock 0.4 0.5 0.6 0.024
Other 1.4 2.5 1.0 0.011
Lesion characteristics (%)
$2 Lesions attempted 29.1 27.0 29.8 , 0.001
Proximal LAD attempted 18.0 17.7 16.8 0.007
Bypass graft attempted 3.5 5.4 6.0 , 0.001
Lesions types
A 81.2 39.8 28.7 , 0.001
B1 8.7† 40.1 39.6 , 0.001
B2 — 12.0 22.5 , 0.001
C 10.1 8.1 9.2 0.015
Devices/medications (%)
Stent — 3.9 48.5 , 0.001
Directional atherectomy 5.2 9.5 3.1 , 0.001
Rotational atherectomy — 3.5 6.1 , 0.001
IIb/IIIa use — — 6.8 —
*Analysis of variance for continuous variables. †During this time period, lesion type could only be coded as A, B, C.
DCA 5 directional coronary atherectomy; LAD 5 left anterior descending coronary artery; MI 5 myocardial infarction.
Table 3. Unadjusted and Adjusted Rates of In-hospital Outcomes After PCI by Year of
Procedure
Characteristic
Year
p Trend*1990–1993 1994–6/95 7/95–1997
Unadjusted rates
Clinical success (%) 88.8 89.2 91.5 , 0.001
MI (%) 2.4 2.1 2.0 , 0.001
Any CABG (%) 3.3 3.3 1.8 , 0.001
Emergency (%) 2.2 2.3 1.3 , 0.001
Nonemergency (%) 1.1 1.0 0.5 , 0.001
Death (%) 1.0 1.1 1.2 0.026
Adjusted Rates
Clinical success* (%) 88.2 89.1 91.9 , 0.001
MI (%) 2.4 2.1 1.9 0.001
Any CABG (%) 3.1 3.3 1.8 , 0.001
Emergency (%) 2.1 2.3 1.3 , 0.001
Nonemergency (%) 1.1 1.0 0.5 , 0.001
Death (%) 1.2 1.1 1.1 0.007
*$1 lesion dilated to ,50% and no MI, CABG or death.
CABG 5 coronary artery bypass grafting surgery; MI 5 myocardial infarction.
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occurring during the same hospitalization dropped from
3.1% to 1.8%, a 40% decrease in this particular adverse
outcome. Adjusted emergency CABG rates declined from
earlier rates of 2.1% to 2.3% to a low of 1.3% recently. A
slight decrease in mortality was noted after controlling for
case mix with a rate of 1.1% in more recent years.
DISCUSSION
The field of interventional cardiology has grown at a
remarkable pace since its inception over 20 years ago.
Accompanying this growth are improvements in patient
care and outcomes. Improvements in technology have oc-
curred both in devices and in adjunctive pharmacologic
therapy; coronary stents (10–12) and glycoprotein IIb/IIIa
inhibitors (7,8) are two prominent examples that have
contributed to better patient outcomes. Northern New
England has seen a dramatic decline in the rates of CABG
during the same hospitalization after PCIs and an associated
increase in the clinical success of these procedures in recent
years. This has occurred in the setting of an aging patient
population with increasing comorbidities.
We attribute the decline in the need for emergency
CABG in our study to the availability of coronary stents.
Review of the data presented in Table 3 reveals that the rate
of this outcome did not begin to decline until 1995, when
stents were introduced, and did not dramatically fall until
1996 and 1997, when stents were involved in 45.2% and
62.4% of cases, respectively. Other authors have also de-
scribed that coronary stent use reduces the incidence of
emergency CABG associated with PCIs (25,26). In 1993,
Lincoff et al. (25) described how patients treated by intra-
coronary stenting for abrupt vessel closure saw a reduction
in the need for emergency bypass surgery when compared
with matched controls (4.9% vs. 18%, p 5 0.02).
However, other factors may be contributing to the im-
proving outcomes, such as increasing operator volume and
hospital experience, improvements in equipment and newer
pharmacologic agents. Although use of glycoprotein IIb/
IIIa inhibitors in our patients had only risen to 12.7% of
cases during 1997, the Evaluation of 7E3 for the Prevention
of Ischemic Complications (EPIC) Investigators noted a
35% reduction in the rate of the adverse clinical events after
high-risk PCIs in patients receiving these agents (7). The
use of the antiplatelet agent ticlopidine has also allowed for
decreased complications associated with coronary stents (6).
At the same time, increasing experience of operators and
hospitals performing these procedures has been shown to
contribute to these improved outcomes (3,4,27). Within our
own registry, most operators performing PCIs in the early
1990s continued to perform PCIs through the end of the
study period, increasing their overall experience over time.
Other investigators have provided information with re-
spect to PCI outcomes in the setting of large, clinical
registries from earlier years. Hannan et al. studied 62,670
PCIs in New York State during 1991 to 1994. They
described a risk-adjusted in-hospital mortality rate of 0.9%
(27) and a CABG rate of 3.43%. Similar event rates were
described by the New Approaches to Coronary Intervention
(NACI) Registry during 1990 to 1994 (15).
Although CABG rates have declined and clinical success
has improved, the rate of overall in-hospital mortality has
seen little change with the evolution of PCIs. King et al.
compared registry data from 1985 to 1986 with data from
1990 to 1994 and noted no difference in one-year survival
after PCIs, after adjustment for case mix (15). Other studies
have reported in-hospital mortality rates of 1% to 2%
(15,27) after PCIs, which is reflected by our own experience.
There are several limitations to our study. For the
purposes of our study, we did not collect information with
respect to the indication for the use of a coronary stent, that
is, stent use as the primary intended device versus treatment
for abrupt closure. This limits our ability to comment on a
cause-and-effect relationship regarding stent use and a
reduction in the rate of emergency CABG. In addition,
although the adverse outcomes including CABG and in-
hospital mortality were validated as part of this study, MIs
after PCI were not validated. Only a slight decrease in
adjusted mortality was seen over time. The statistical sig-
nificance of this slight decrease may be a reflection of the
large number of patients studied. Alternatively, our models
may not completely account for the impact of the more
critically ill patient population seen in recent years, includ-
ing a higher proportion of patients with acute MI or
cardiogenic shock. Our experience describes the outcomes
within one region of the U.S. Previous studies have shown
that New England practitioners are relatively conservative
with the use of cardiac catheterization and PCIs when
compared with other regions of the country (28). Whether
our results may be extrapolated to the remainder of the
country remains to be seen.
Over time, a significant reduction in major adverse
clinical events has been seen in northern New England after
PCIs. This has occurred in the setting of an aging patient
population with greater preprocedure comorbidity. These
improvements are likely related to the increasing experience
of the operators, the advent of new technology and possibly,
the sharing of outcomes data within our region to help
guide decision making for our patient population. Our large
regional database allows our physicians to better assess the
outcomes of their patients using analyses of current data.
Although more work must be done with respect to improv-
ing in-hospital mortality as well as determining how our
patients fare after discharge, the practice of interventional
cardiology has seen significant improvements in in-hospital
outcomes over time.
APPENDIX A
Predicted ejection fraction 5 71.98794 1 [(20.09095 3
age) 1 (1.69334 3 gender) 2 (0.19939 3 left ventricular
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end diastolic pressure) 2 (4.20875 3 history of previous
MI) 2 (3.77906 3 history of previous CABG) 2 3.6]
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Fedele, MD, Louis I. Fink, MD, Erik J. Funk, MD, Alan
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Edward Palank, MD, M. Judith Porelle, RN, Donna
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MD, Thomas P. Wharton, MD, Kirke W. Wheeler, MD,
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